JPWO2023081752A5 - - Google Patents

Info

Publication number
JPWO2023081752A5
JPWO2023081752A5 JP2024526511A JP2024526511A JPWO2023081752A5 JP WO2023081752 A5 JPWO2023081752 A5 JP WO2023081752A5 JP 2024526511 A JP2024526511 A JP 2024526511A JP 2024526511 A JP2024526511 A JP 2024526511A JP WO2023081752 A5 JPWO2023081752 A5 JP WO2023081752A5
Authority
JP
Japan
Prior art keywords
response
car
cells
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540275A5 (https=
JP2024540275A (ja
Publication date
Priority claimed from PCT/CN2021/128578 external-priority patent/WO2023077343A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/079216 external-priority patent/WO2023081752A1/en
Publication of JP2024540275A publication Critical patent/JP2024540275A/ja
Publication of JP2024540275A5 publication Critical patent/JP2024540275A5/ja
Publication of JPWO2023081752A5 publication Critical patent/JPWO2023081752A5/ja
Pending legal-status Critical Current

Links

JP2024526511A 2021-11-04 2022-11-03 Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照 Pending JP2024540275A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275471P 2021-11-04 2021-11-04
CNPCT/CN2021/128578 2021-11-04
US63/275,471 2021-11-04
PCT/CN2021/128578 WO2023077343A1 (en) 2021-11-04 2021-11-04 Bcma-targeted car-t cell therapy for multiple myeloma
PCT/US2022/079216 WO2023081752A1 (en) 2021-11-04 2022-11-03 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (3)

Publication Number Publication Date
JP2024540275A JP2024540275A (ja) 2024-10-31
JP2024540275A5 JP2024540275A5 (https=) 2025-11-11
JPWO2023081752A5 true JPWO2023081752A5 (https=) 2025-11-11

Family

ID=84370104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526511A Pending JP2024540275A (ja) 2021-11-04 2022-11-03 Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照

Country Status (11)

Country Link
US (1) US20230277589A1 (https=)
EP (1) EP4426737A1 (https=)
JP (1) JP2024540275A (https=)
KR (1) KR20240117530A (https=)
CN (1) CN118510801A (https=)
AU (1) AU2022381186A1 (https=)
CA (1) CA3237341A1 (https=)
IL (1) IL312602A (https=)
JO (1) JOP20240104A1 (https=)
MX (1) MX2024005461A (https=)
WO (1) WO2023081752A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020378263A1 (en) 2019-11-05 2022-06-23 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025076341A1 (en) * 2023-10-05 2025-04-10 Janssen Biotech, Inc. Improved methods in lentiviral manufacturing for production of car-t cell drug products
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
US20250269024A1 (en) * 2024-02-05 2025-08-28 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP4282877A3 (en) * 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
JP2021532742A (ja) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. Ｎｅｆを含むｔ細胞及びその生成方法

Similar Documents

Publication Publication Date Title
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2018522833A (ja) キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療
ES2783448T3 (es) Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
TW200521142A (en) CD40 antibody formulation and methods
US20190314390A1 (en) Ep4 inhibitors and use thereof
CN102884081A (zh) 用dll4拮抗剂治疗自身免疫疾病的方法
JP2022532229A (ja) 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用
CN118662516A (zh) 施用嵌合抗原受体免疫疗法的方法
CN107614530A (zh) 用于多发性骨髓瘤（mm）的治疗
JP2025175307A (ja) 逐次抗ｃｄ１９治療
JP2013193995A (ja) 特発性炎症性筋疾患の予防又は治療剤
JPWO2023081752A5 (https=)
CN119095869A (zh) 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞
WO2022257937A1 (zh) 用于细胞免疫治疗的方法和组合物
US20240139241A1 (en) Compositions and methods for conditioning patients for cell therapy
TW202120550A (zh) 雙特異性蛋白質
JPWO2022117068A5 (https=)
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
US20250333530A1 (en) Combination treatment of glofitamab and chemotherapy
WO2023159176A1 (en) Combination therapy for b-cell disorders
WO2023144702A1 (en) Combination therapy for cancer
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
WO2026040955A1 (zh) 双特异性抗cd3/cd20多肽复合物的用途